UCARTMESO / Cellectis - LARVOL DELTA

Mesothelin (MSLN) targeting allogeneic CAR T cells engineered to overcome tumor immunosuppressive microenvironment (SITC 2021) - "TRAC KO limits the risk of GvHD, while CD52 KO allows the use of alemtuzumab in the preconditioning regimen. The data shows that cells not edited at the TGFBR2 locus are unable to be activated upon target exposure in the presence of TGFβ, while edited cells were activated in the presence of TGFβ, triggering CD25 expression at similar levels as those of cells activated in the absence of TGFβ. Conclusions Altogether, we have demonstrated potent antitumor activity in vitro and in vivo, and that addition of the third knock-out of TGFBR2 gene provide valuable additional properties to UCARTMeso cells, representing a very attractive strategy for their use in the treatment of solid tumors."

CAR T-Cell Therapy • Gastrointestinal Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pancreatic Cancer • Solid Tumor • CD52 • MSLN • TGFBR2

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer (GlobeNewswire) - "The preclinical data demonstrated potent activity of UCARTMESO in vitro and in vivo against MSLN expressing cell lines, and in vivo activity in pancreatic and pleural mesothelioma mouse models. Due to TGFBR2 KO, UCARTMESO was shown to restore IL2RA upregulation upon in vitro activation, even in media rich in TGFB1, which contributes to the immune suppressive microenvironment in tumors."

Preclinical • Oncology • Solid Tumor

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire) - "Cellectis...announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), to be held in Washington, D.C. and virtually on November 10 to 14, 2021. Cellectis will present a poster on UCARTMESO, an allogeneic CAR-T cell product candidate targeting mesothelin - expressing solid tumors."

Preclinical • Oncology • Solid Tumor

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021 (GlobeNewswire) - “Cellectis continues to build its UCART pipeline and advance product candidates with industry leading partners. Cellectis anticipates the filing of two investigational new drug (IND) applications for UCART20x22 and UCARTMESO in 2022.”

IND • Hematological Malignancies • Oncology • Solid Tumor

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities (GlobeNewswire) - "Cellectis outlines four new UCART preclinical programs, targeting solid tumors: (i)UCART20x22 ; the first allogeneic dual CAR T-cell candidate product for B-cell malignancies: Preclinical data show that UCART20x22 is able to kill tumor cells bearing CD20 even in the absence of CD22 antigen; (ii) UCARTMESO for mesothelin-expressing solid tumors: Preclinical data shows that TGFBR2-edited MESO CAR T-cells, exhibit high anti-tumor activity in vitro and in vivo."

Preclinical • Hematological Malignancies • Oncology